Scott Herfel, PA
Surgical · Setauket, NYNPI 1427082387
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,636 of the $5,789 with a category attached, or 80.1%. 33 manufacturers reported payments, led by Johnson & Johnson at 24.2% of the total. 2025 is the largest year on record at $2,170, 2.5 times the $871 reported in 2021. Among surgical clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 170 payments — averaging $34.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Novo Nordisk$729
- Astellas Pharma US Inc$369
- Coloplast$368
- Myriad Genetic Laboratories, Inc.$332
- Urogen Pharma, Inc.$311
- plus $2K from 27 others
What the payments were for
- Consulting fees$72913%
- Food & beverage$4,63680%
- Education$4247%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 28 | $1,400 |
| Novo Nordisk | 2 | $729 |
| Astellas Pharma US Inc | 21 | $369 |
| Coloplast | 15 | $368 |
| Myriad Genetic Laboratories, Inc. | 14 | $332 |
| Urogen Pharma, Inc. | 8 | $311 |
| Ferring Pharmaceuticals Inc. | 11 | $273 |
| Bayer | 8 | $196 |
| Procept Biorobotics Corporation | 1 | $186 |
| Blue Earth Diagnostics | 8 | $170 |
| Boston Scientific | 2 | $144 |
| Sumitomo Pharma America, Inc. | 5 | $130 |
| Amgen | 1 | $122 |
| Dentsply IH AB | 5 | $115 |
| Teleflex LLC | 2 | $107 |
| Telix Pharmaceuticals | 4 | $103 |
| Alnylam Pharmaceuticals Inc. | 6 | $101 |
| Immunitybio, Inc. | 3 | $81 |
| Laborie Medical Technologies Corp. | 2 | $70 |
| Endo Pharmaceuticals Inc. | 1 | $63 |
| Hollister Incorporated | 4 | $56 |
| Photocure Inc | 2 | $46 |
| Tolmar, Inc. | 2 | $42 |
| Myovant Sciences Inc. | 2 | $39 |
| Tolmar Pharmaceuticals, Inc. | 2 | $38 |
| Pfizer | 2 | $36 |
| Dentsply IH Inc. | 2 | $35 |
| Endo USA, Inc. | 2 | $32 |
| Civco Medical Instruments | 1 | $21 |
| Urovant Sciences Inc | 1 | $21 |
| Clarus Therapeutics Inc. | 1 | $21 |
| Progenics Pharmaceuticals, Inc. | 1 | $20 |
| Travere Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rivfloza$729
- Erleada$358
- RYBREVANT$254
- CARVYKTI$254
- AquaBeam Robotic System$186
- Porges Coloplast$137
- JELMYTO$129
- AKEEGA$125
- UPLIZNA$122
How this compares
$5,789 in reported general payments places this provider in the 95th percentile of 1,544 surgical providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 180 | $152,079 |
| Potassium Citrate ErPotassium Citrate | 272 | $41,822 |
| GemtesaVibegron | 31 | $37,486 |
| Solifenacin Succinate | 167 | $16,833 |
| Mirabegron ErMirabegron | 17 | $12,275 |
| Tamsulosin Hcl | 541 | $10,417 |
| Methenamine Hippurate | 73 | $5,544 |
| Desmopressin AcetateDesmopressin (Nonrefrigerated) | 29 | $3,311 |
| Finasteride | 265 | $3,220 |
| Tadalafil | 18 | $3,042 |
| Silodosin | 13 | $2,595 |
| Desmopressin Acetate | 28 | $2,467 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 118 | $2,452 |
| Oxybutynin Chloride ErOxybutynin Chloride | 77 | $2,256 |
| Tolterodine Tartrate ErTolterodine Tartrate | 19 | $1,419 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $369 | $152,079180 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $130 | $37,48631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,544 surgical providers in New York.
Other surgical in Setauket
- Lindsay SchweikarthAlbany$324K
- Nicole FeinNew York$225K
- Kenneth RuizNew York$93K
- Terry LinNew York$70K
- Beth PhillipsEast Syracuse$51K
- James DoolittleNew York$46K
- Tanya GeistAmherst$43K
- Irina KommNew York$39K
- Sarah MartineckWilliamsville$34K
- Richard DalabaAlbany$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.